1



Board -2014 -Mtg -3-Doc 03


3 December 2014
Dear Board members
Eight months ago, we met in Berlin for a pivotal Board Retreat to debate the
building blocks of Gavi?s 2016 -20 strategy. In eight weeks ? time , another meeting
in Berlin will determine whether the Alliance is fully funded to deliver on that
strategy. Whe n Gavi?s history is written, the se two meetings in the German
capital may be seen as the defining moments of this period .
There has of course been a huge amount achieved between those meetings. In
2014, we saw the 73 rd ? and final ? Gavi country launch pentavalent vaccine; we
achieved our vaccine intro duction targets for this strategy period for pentavalent,
pneumococcal and rotavirus vaccines; we saw nearly every Gavi country apply
for inactivated polio vaccine (IPV) support; we reached more children than ever
before with routine immunisation; we saw r ecord levels of co -financing; we
achieved the lowest weighted average price ever for our main three vaccines ; we
agreed on our 2016 -20 strategy framework; and we made great strides to being
fully replenished. We also continue to work hard to address the ma jor challenges
we face including coverage and equity of immunisation, challenging political
situations in some countries, more countries defaulting on co -financing as their
payments increase, enhancing risk management, and growing fiscal pressure in
a numb er of donor markets. Looking back on 2014, I am proud of the progress
we have made in continuing to accelerate access to the wonder of immunisation.
Immunisation : more critical than ever
Our Board meeting comes at a time when the world is being reminded of the
grave threat still posed by infectious disease. Ebola , and its tragic impact on the
population of affected countries, has been prominent in the global news agenda.
But we are also witnessing a resurgence of measles, with many developed
countries exper iencing their highest number of cases in decades, while polio
continues to stubbornly elude the final push for elimination. These events are a
reminder of the power of immunisation and importance of Gavi .
Report of the Chief Executive Officer

Report to the Gavi Board
10 -11 December 2014

Board -201 3-Mtg -1-Doc 00b


GAVI Alliance Board Meeting
11 -12 June 2013
Starling Hotel, Geneva, Switzerland

Monday 10 June : Pre -Board meetings
Tuesday 11 June : 0 8.30 -18. 15 (Board meeting Day One)
Wednesday 12 June : 0 9.00 -17.30 (Board meeting Day Two)
Quorum: 14

Agenda


UPDATED - Pre -Board Meetings ? Monday, 10 June 2013
Item Subject Room Schedule
Pre -Board meetings
? Technical Briefing Montana 10.30 -12.30
? AMC annual s takeholders ? meeting Villars 11.00 -13.00
? GAVI Do nors? meeting Saas Fee 12.00 -14.30
? GAVI Donors? consultation on revisions to GAVI
TAP and Gender Policies
Saas Fee 14. 30 -15. 30
? Developing Countries Board members meeting Montana 14.00 -16.30
? All Chairs meeting Villars 13.30 -14.30
? Governance Committe e meeting Arosa 14.45 -15.45
? Executive Committee meeting Villars 16.00 -17.00
? IFFIm Donors? Meeting Saas Fee 17.00 -18.30
? Closed Executive Session Montana 17.30 -19.00
? IFFIm Board meeting Arosa 19.30 -21. 15

Seth Berkley, MD
Chief Executive Officer
CEO Board report


GAVI Alliance Board meeting
Dar es Salaam, United Republic of Tanzania
4 -5 December 2012
GAVI Alliance Board meeting
4-5 December 2012
Tanzania ? pneumococcal and rotavirus dual
launch 6 December
2
Photo: Rift Valley Children's Fund -USA, Inc

Marie -Ange Saraka -Yao
David Ferreira
Long term funding strategy
GAVI Alliance Board meeting
Dar es Salaam, Tanzania, 4 -5 December 2012
GAVI Alliance Board meeting
4-5 December 2012
Building on the Alliance?s success

2000 -11 2011 -15 2016 -20
1
Contribute to
averting
4 million future
deaths
Contribute to
averting approx.
5 million future
deaths

Contribute to
averting
over 5.5 million
future deaths
Driven by the introduction
of pentavalent vaccines
Driven by scaled up
pentavalent vaccine
launches, and introduction
of pneumococcal and
rotavirus vaccines
Driven by scaled up rollouts
of the current vaccine and
HSS portfolio, as well as
introducing potential other
vaccines (subject to the VIS)

1

Report to the
GAVI Alliance Board

Board -2012 -Mtg -3-Doc 03
4-5 December 2012
Report of the Chief Executive Officer


27 November 2012
Dear Board Members,

It gives me great pleasure to provide this report on the eve of our Board meeting in
the United Republic of Tanzania, which will begin a significant week f or the Alliance
as we see more than 60 0 friends of GAVI gather at our Partners? Forum to consider
what progress we have together made and how we can collectively build upon it.

I would like to th ank the Government of Tanzania ? from the President down ? for the
support they have provided for the Board meeting and the Partners? Forum.
Tanzania has much to be proud of. In 1999, 147 out of every 1000 children died
before their fifth birthday. That figure was down to 67 in 2011, putting Tanzania on
track to meet the Millennium Development Goal on child mortality. One of the
reasons for that impressive reduction has been the work that Tanzania has done with
our Alliance. In 2001, Tanzania was one o f the first countries to be supported by
GAVI to use the then ne w DTP -HepB combination vaccine. We then supported the
introduction of pentavalent vaccine in 2009, which now reaches 90% of Tanzania?s
children. And Tanzania will take another dramatic step this week in protecting its
children against the two biggest child killers ? pneumonia and severe diarrhoea,
which cause a quarter of under five d eaths in Tanzania ? by introducing
pneumococcal and rotavirus vaccines.

The Forum will also give us the opportunity to mark a new phase in the Decade of
Vaccines following the approval earlier in the year by the World Health Assembly of
th e Global Vaccine Action Plan. At the AFRO regional committee meeting in Angola
two weeks before our Board meeting I had the chance to discuss with health
ministers how they are planning to meet the ambitious Plan, and how GAVI can help.
The week before that I was in Bra zil, where the Brazilian government renewed its
commitment to work with GAVI and start contributing to IFFIm ? although the path
through the Brazilian bureaucracy is still not entirely clear . I am sure that Dagfinn
H?ybr?ten, chair of the Board, will update the Board on his visit with Australian and
New Zealand MPs and Helen Evans to Myanmar; from what I have heard and seen of
the media coverage, it was a highly successful visit.

Accelerated introductions

The pace of the Alliance?s work continues to accele rate: by the end of 2012 we will
have seen a record total of 30 vaccine introductions into countries? routine schedules
and 6 campaigns supported by GAVI over the course of the year. These include five
pentavalent, seven rotavirus, ten pneumococcal, and e ight measles second dose

 

Evaluation Advisory Committee Meeting
5 July 2012
EAC -2012 -Mtg -3a 1




GAVI Alliance Evaluation Advisory Committee Meeting
5 July 2012
Geneva, Switzerland


FINAL MINUTES


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 09.45
Geneva time on 5 July 2012. Sania Nishtar , Committee Chair, participating by
videoconference, chaired the meeting. Rob Moodie co -chaired.

1.2 Standing declarations of interest were tabled to the Committe e (Doc 1a ). Alan
Hinman noted that the Novartis research grant reported was for rabies rather
than measles.

1. 3 The Committee noted the minutes of its meeting of 19 -20 January 2012 in
Geneva (Doc 1b) and its teleconference of 13 February 2012 (Doc 1c) .
The se minutes were approved by no objection on 23 April 201 2.

1.4 The Chair updated the EAC on the GAVI Alliance Board meeting which had
taken place in Washington D.C. in June 2012 and at which she had reported
on the activities of the EAC. The Board had approved the Evaluation Policy
and considered the EAC engagement with the evaluation of GAVI support to
CSOs as quite productive. She had updated the Board on the EAC?s role in
reviewing and approving the Request for Proposals for the Advance Market
Commit ment for Pneumococcal Vaccine Process and Design Evaluation , as
well as the process in relation to the Full Country Evaluations.

1.5 During a short meeting with Dagfinn H ?ybr ?ten, GAVI Alliance Board Chair,
the EAC Chair had briefly discussed the w ork of the EAC feeding into policy
as well as the changing landscape of health with respect to the post MDG
landscape. A short discussion on the latter is recorded under Item 9.

--- ---

2. Update from the Secretariat

2.1 Nina Schwalbe, Managing Director, Policy and Performance, reported to the
EAC that the Secretariat has been working on updating the mission indicators
and that the Board has been provided with progress reports on Key
Performance Indicators and the GAVI All iance risk register.